Vir Biotechnology, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Vir Biotechnology, Inc. (VIR) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-05
- Vir Biotechnology, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00.
- Vir Biotechnology, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was -$262.00K.
- Vir Biotechnology, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $0.00.
- Vir Biotechnology, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-30 was $0.00.
- Vir Biotechnology, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $7.33M.
- Vir Biotechnology, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00.
- Vir Biotechnology, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Vir Biotechnology, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $4.05M, a 94.76% decline from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 | ||||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$262.00K derived: sum of 2 quarters · filed 2026-02-23 | $7.33M 10-K · filed 2026-02-23 | ||
| 2025-09-30 | -$262.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $7.33M 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $7.59M 10-Q · filed 2026-08-05 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | $0.00 10-K · filed 2026-02-23 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-06 | ||||
| 2023-12-31 | $0.00 10-K · filed 2026-02-23 | $957.00K 10-K · filed 2024-02-26 | |||
| 2022-12-31 | $77.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $104.00K derived: sum of 2 quarters · filed 2024-02-26 | $824.00K derived: sum of 3 quarters · filed 2024-02-26 | $4.05M 10-K · filed 2024-02-26 | |
| 2022-09-30 | $27.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $747.00K derived: sum of 2 quarters · filed 2022-11-03 | $3.97M 10-Q · filed 2022-11-03 | $81.07M derived: sum of 4 quarters · filed 2024-02-26 | |
| 2022-06-30 | $720.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $3.94M 10-Q · filed 2022-08-09 | $81.04M derived: sum of 3 quarters · filed 2024-02-26 | $81.13M derived: sum of 4 quarters · filed 2024-02-26 | |
| 2022-03-31 | $3.22M 10-Q · filed 2022-05-05 | $80.32M derived: sum of 2 quarters · filed 2024-02-26 | $80.41M derived: sum of 3 quarters · filed 2024-02-26 | ||
| 2021-12-31 | $77.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $77.19M derived: sum of 2 quarters · filed 2024-02-26 | $77.19M 10-K · filed 2024-02-26 | ||
| 2021-09-30 | $90.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $90.00K 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-09 | ||||
| 2020-12-31 | $48.49M 10-K · filed 2023-02-28 | $48.50M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |